Rituximab treatment in myasthaenia gravis: Report of two paediatric cases

Roshan Koul*, Amna Al-Futaisi, Rana Abdelrahim, Renjith Mani, Reem Abdwani, Abdullah Al-Asmi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.

Original languageEnglish
Pages (from-to)e223-e227
JournalSultan Qaboos University Medical Journal
Issue number2
Publication statusPublished - May 2018


  • Case Report
  • Children
  • Cholinergic Receptors
  • Myasthenia Gravis
  • Oman
  • Rituximab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rituximab treatment in myasthaenia gravis: Report of two paediatric cases'. Together they form a unique fingerprint.

Cite this